Clinical-stage biotech PharmAust has submitted a request for orphan medicinal product designation (OMPD) to the European Medicines Agency (EMA) for...
Vous n'êtes pas connecté
Neurotech has submitted a request with the US Food and Drug Administration for orphan drug designation (ODD) for use of ...
Clinical-stage biotech PharmAust has submitted a request for orphan medicinal product designation (OMPD) to the European Medicines Agency (EMA) for...
The US Food and Drug Administration (FDA) has awarded a Breakthrough Device Designation to Neuralink’s latest brain implant device, Blindsight. This...
The US Food and Drug Administration (FDA) has awarded a Breakthrough Device Designation to Neuralink’s latest brain implant device, Blindsight. This...
ATLANTA, USA, (CDC) – Half a million fewer US youth reported current use of e-cigarettes in 2024 compared to 2023, according to new data from the...
By Shen Pei-yao and Ko Lin TAIPEI, Taiwan, (CNA) – The Taiwan Food and Drug Administration (TFDA) has amended a regulation to allow food industry...
By Shen Pei-yao and Ko Lin TAIPEI, Taiwan, (CNA) – The Taiwan Food and Drug Administration (TFDA) has amended a regulation to allow food industry...
THURSDAY, Sept. 5, 2024 -- The maker of the ADHD drug Vyvanse has been given approval by the U.S. Drug Enforcement Administration to make more of the...
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...